Myeloproliferative neoplasm laboratory findings: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 54: Line 54:
==Gallery==
==Gallery==
<gallery widths=200px class="center">
<gallery widths=200px class="center">
MPN-FISH.jpg|Representative Philadelphia negative metaphase bone marrow cell with a t(9;12)(q34;p13) translocation. (a) G-banded karyotype; (b) FISH analysis demonstrates lack of BCR-ABL1 fusion but reveals a small third signal from the ABL1 probe (arrow) and; (c) The ETV6 split signal (arrowed in red) on der(9)t(9;12) from the break-apart FISH probe shows the gene rearrangement and confirms G banding results. The red/green fusion signal marks the normal gene.</gallery>
MPN-FISH.jpg|Representative Philadelphia negative metaphase bone marrow cell with a t(9;12)(q34;p13) translocation. (a) G-banded karyotype; (b) FISH analysis demonstrates lack of BCR-ABL1 fusion but reveals a small third signal from the ABL1 probe (arrow) and; (c) The ETV6 split signal (arrowed in red) on der(9)t(9;12) from the break-apart FISH probe shows the gene rearrangement and confirms G banding results. The red/green fusion signal marks the normal gene.<ref name="GanchevaVirchis2013">{{cite journal|last1=Gancheva|first1=Katya|last2=Virchis|first2=Andres|last3=Howard-Reeves|first3=Julie|last4=Cross|first4=Nick CP|last5=Brazma|first5=Diana|last6=Grace|first6=Colin|last7=Kotzampaltiris|first7=Paul|last8=Partheniou|first8=Fedra|last9=Nacheva|first9=Elisabeth|title=Myeloproliferative neoplasm with ETV6-ABL1 fusion: a case report and literature review|journal=Molecular Cytogenetics|volume=6|issue=1|year=2013|pages=39|issn=1755-8166|doi=10.1186/1755-8166-6-39}}</ref></gallery>
 
==References==
==References==



Revision as of 19:05, 27 October 2015

Myeloproliferative Neoplasm Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating myeloproliferative neoplasm from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myeloproliferative neoplasm laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myeloproliferative neoplasm laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myeloproliferative neoplasm laboratory findings

on Myeloproliferative neoplasm laboratory findings

Myeloproliferative neoplasm laboratory findings in the news

Blogs on Myeloproliferative neoplasm laboratory findings

Directions to Hospitals Treating Myeloproliferative neoplasm

Risk calculators and risk factors for Myeloproliferative neoplasm laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]

Overview

Laboratory findings consistent with the diagnosis of myeloproliferative neoplasm include leukocytosis, thrombocytopenia, and anemia.

Laboratory Findings

Laboratory findings associated with myeloproliferative neoplasm include:[1][2][3][4]

  • Blood chemistry
  • The following blood levels may be elevated:
  • Bleeding and clotting factor
  • The following blood levels may be elevated:
  • Cytochemistry helps determine the type of cells that are present
  • Flow cytometry helps determine the type of cells that are present
  • Chromosome changes that may occur in some people with leukemia include:
  • Similar to cytogenetics, but more specific
  • Polymerase chain reaction
  • Helpful to detect specific abnormalities in blood or bone marrow cells. Abnormalities can be found even if very few leukemia cells are present in a tissue sample.
  • Neutrophil alkaline phosphatase level
  • Vitamin B12 (or B12 binding capacity)
  • Serum urate

Gallery

References

  1. Canadian Cancer Society.2015.http://www.cancer.ca/en/cancer-information/cancer-type/leukemia-chronic-myelogenous-cml/diagnosis/?region=ab
  2. James W. Vardiman (2009). "Chronic myelogenous leukemia, BCR-ABL1+". American journal of clinical pathology. 132 (2): 250–260. doi:10.1309/AJCPUN89CXERVOVH. PMID 19605820. Unknown parameter |month= ignored (help)
  3. Sánchez-Muñoz, Laura; Alvarez-Twose, Ivan; García-Montero, Andrés C; Teodosio, Cristina; Jara-Acevedo, María; Pedreira, Carlos E; Matito, Almudena; Morgado, Jose Mario T; Sánchez, Maria Luz; Mollejo, Manuela; Gonzalez-de-Olano, David; Orfao, Alberto; Escribano, Luis (2011). "Evaluation of the WHO criteria for the classification of patients with mastocytosis". Modern Pathology. 24 (9): 1157–1168. doi:10.1038/modpathol.2011.84. ISSN 0893-3952.
  4. Levene, Malcolm I.; Lewis, S. M.; Bain, Barbara J.; Imelda Bates. Dacie & Lewis Practical Haematology. London: W B Saunders. p. 586. ISBN 0-443-06377-X.
  5. Gancheva, Katya; Virchis, Andres; Howard-Reeves, Julie; Cross, Nick CP; Brazma, Diana; Grace, Colin; Kotzampaltiris, Paul; Partheniou, Fedra; Nacheva, Elisabeth (2013). "Myeloproliferative neoplasm with ETV6-ABL1 fusion: a case report and literature review". Molecular Cytogenetics. 6 (1): 39. doi:10.1186/1755-8166-6-39. ISSN 1755-8166.

Template:WH Template:WS